Nanoform Reports Strong Growth and Advances in Nanoparticle Drug Development Pipeline
核心洞察
Nanoform (搜索) achieved record project signings in 2024 with revenue growth of 87% in Q4, marking a strong recovery after six quarters of decline.
The company is advancing three key product developments - Nanoenzalutamide (搜索), Nanoapalutamide (搜索), and Nanoencorafenib (搜索) - with deal discussions intensifying and expected closures in coming months.
Nanoenzalutamide (搜索)'s pivotal bioequivalence studies are set to begin in Q2 2025, targeting a 2027/28 market launch as a patient-friendly alternative to Xtandi® with reduced pill burden.
Nanoform (搜索) Finland Plc reported significant progress in its nanoparticle medicine development programs, with strong financial performance and advancement of key clinical projects in 2024. The company's revenue grew by 87% to EUR 0.8 million in Q4 2024, compared to EUR 0.4 million in the same period last year.
The company's flagship project, Nanoenzalutamide (搜索), has reached a critical phase with manufacturing of GMP material for pivotal studies operating in a three-shift pattern. The scale-up has achieved nearly 100-fold increase from previous pilot study campaigns, demonstrating the company's manufacturing capabilities.
"After six quarters of negative revenue growth, we have seen strong momentum during the last two quarters and we expect this to continue," stated CEO Edward Hæggström. "The growth will be fuelled not only by non-GMP and GMP projects but also from development, exclusivity and milestone payments."
Strategic Product Development Pipeline
Nanoform (搜索)'s three lead products - Nanoenzalutamide (搜索), Nanoapalutamide (搜索), and Nanoencorafenib (搜索) - represent the company's innovative approach to improving existing medications through nanocrystalline formulation. These developments aim to address limitations of current amorphous solid dispersion (ASD) formulations, particularly focusing on reducing pill burden for patients.
Nanoenzalutamide (搜索), targeting the $6 billion Xtandi® market, is positioned to offer a significant advantage by reducing dosing from four tablets to just one. The product is expected to launch in 2027/28 in the US/EU markets, following the planned bioequivalence studies starting in early Q2 2025.
Environmental and Technical Advantages
The company's CESS® technology offers environmental benefits over traditional pharmaceutical manufacturing processes. Unlike conventional spray drying methods that require large amounts of organic solvents, Nanoform (搜索)'s process uses recycled CO2, aligning with pharmaceutical industry sustainability goals.
Financial Performance and Growth
The company reported annual revenue of EUR 2.8 million for 2024, derived from 43 different customer projects. The gross margin improved to 80%, despite impact from external GMP QC costs related to the nanoenzalutamide (搜索) project. Employee count increased by 10% to 181 personnel.
Business Development and Partnerships
Nanoform (搜索) has expanded its collaborative efforts, including a strategic partnership with CBC Co., Ltd. (搜索) for the Japanese market and a development agreement with Takeda Pharmaceuticals (搜索) for plasma-derived therapy formulations. The company also secured a EUR 4.3 million grant from Business Finland for research and development of nanoparticle-enabled formulation platforms.
Future Outlook
The company plans to announce its mid-term business targets for 2030 during 2025. Near-term objectives include signing multiple development and commercial agreements for product kernels, completing the first pivotal bioequivalence study with a nanoformed medicine, and improving free cash flow compared to 2024.